chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 33.0
Sex: M
Vaccine: FLU4
Symptoms: Body temperature increased, Malaise
Clinical narrative: This spontaneous case, reported by other health professional to VAERS and initially retrieved on 21-Feb-2018 by Seqirus from VAERS (VAERS ID: 720487), concerning a 33-year-old, adult male patient. The patient's medical history and concomitant medications were not reported. On 13-Oct-2017, the patient received AFLURIA QUADRIVALENT (dose: 0.5 ml, route of administration: intramuscular, anatomical location: left arm, batch number and expiry date: not reported). On 14-Oct-2017, after 1 day of vaccination, the patient had temperature of 102-degree Fahrenheit and malaise for about 24 hours. At the time of this report, the outcome of the events (malaise and body temperature increased) was not reported. The reporter assessed this case as non-serious.
Sex: F
Vaccine: FLU4
Symptoms: Hypersensitivity, Pruritus, Rash generalised
Clinical narrative: This spontaneous case, reported by other health care professional to VAERS and initially retrieved on 21-Feb-2018 by Seqirus from VAERS (VAERS ID: 720655), concerns a 32-year-old, adult, female patient. The patient's current condition included allergy to eggs (on an unspecified date). The concomitant medications were not reported. On 09-Oct-2017 (approximately at 1:30 pm), the patient was administered with AFLURIA QUADRIVALENT (dose: 0.5 ml (1 as reported), route of administration: intramuscular, anatomical location: left arm, batch number: 00944611A and expiry date: not reported). On the same day, after vaccination, it was reported that the patient did not experience any symptoms of allergic reactions till 4 pm, but after that she had rash all over the body and felt itchy. The patient did not experience difficulty of breathing or cardiopulmonary distress, neurological symptoms or change in sensorium as well. The patient forgot to tell the nurse about her egg allergy. On an unspecified date the patient was treated with epinephrine 0.5 ml intramuscularly in to the anterolateral aspect of the thigh region. After 5-10 minutes, the symptoms were subsided mostly and after 30 minutes, the patient felt much better and all rashes were recovered. The patient did not received 2nd dose of epinephrine. The patient was recommended for emergency room visit for further follow-up as anaphylaxis might reoccur after several hours. At the time of report, the patient had recovered from the events (allergic reaction, rash all over and itchy rash). The reporter assessed the events as non-serious.
Sex: M
Vaccine: FLU4, PPV
Symptoms: Blood pressure increased, Erythema, Peripheral swelling, Pruritus
Clinical narrative: This is spontaneous case, reported by other healthcare professional to VAERS and initially retrieved on 21-Feb-2018 by Seqirus from VAERS (VAERS ID: 720791), concerns an 84-year-old male patient. The patient's historical conditions included depression, BPH (benign prostatic hyperplasia), eczema, CAD (coronary artery disease), reflux, hernia, dementia. On 12-Oct-2017, the patient was administered with AFLURIA QUADRIVALENT (dose: 0.5ml, batch number: XF31307, route of administration: unknown, anatomical location: right arm). On 12-Oct-2017, the patient was administered with co-suspect PNEUMOVAX (dose: 2 (as reported), batch number: N013521, route of administration: unknown, anatomical location: left leg). On an unspecified date, the patient was presented to clinic two days after receiving AFLURIA QUADRIVALENT (suspect) and PNEUMOVAX (co-suspect) with elevated blood pressure at home. The patient took atenolol and Lisinopril at 11:45 am on an unspecified date in Oct-2017. The patient's blood pressure was 136/105 (in triage) and 180/80 at 14:45. The patient also had redness and swelling in left upper arm. The patient stated that, he had a pneumonia vaccine on 12-Oct-2017 and started to swell and itch shortly after administration. The outcome of the events was unknown. The reporter assessed the events as non-serious.
Age: 76.0
Sex: F
Vaccine: FLU4
Symptoms: Pruritus, Urticaria
Clinical narrative: This spontaneous case, reported by health care professional (other) to VAERS and initially retrieved on 21-Feb-2018 by Seqirus from VAERS (VAERS ID: 721115), concerns a 76-year-old elderly female patient. The patient's concomitant medications included methylprednisolone, cimetidine, ZYRTEC, HCTZ, lovastatin, Vitamin D, aspirin and meloxicam for an unknown indication. On 05-Oct-2017, the patient was administered with AFLURIA QUADRIVALENT (dose: 0.5 ml, route of administration: intramuscular, anatomical location: right arm, batch number and expiry date: not reported). On an unspecified date, after the administration of vaccine, the patient experienced itching of the skin on arms, legs and trunk. It was reported that, the lesions were like wheel on thighs. The patient was treated with DEPO MEDROL (80 mg, injection). At the time of this report, the outcome of the events was unknown. The reporter assessed the case as non-serious.
Sex: F
Vaccine: FLU4
Symptoms: Injection site erythema, Injection site pruritus
Clinical narrative: This is spontaneous case, reported by other health professional to VAERS and initially retrieved on 21-Feb-2018 by Seqirus from VAERS (VAERS ID: 721271), concerns a 48-year-old, adult female patient. On 17-Oct-2017, the patient received AFLURIA QUADRIVALENT (dose: 0.5ml, batch number: XF31507, anatomical location: left arm, route of administration: intramuscular). On the same day, the patient had itchiness and redness at the site of injection. At the time of this report, the patient recovered from the events (injection site erythema and injection site pruritus). The reporter assessed the case as non-serious.
Age: 50.0
Sex: F
Vaccine: FLU4
Symptoms: Injection site erythema, Injection site swelling
Clinical narrative: This is spontaneous case, reported by other health professional to VAERS and initially retrieved on 21-Feb-2018 by Seqirus from VAERS (VAERS ID: 721283), concerns a of 50-year-old adult female patient. The patient had no medical history and no medications at the time of vaccination. The patient had no medical history and no medications at the time of vaccination. On 17-Oct-2017, the patient was administered with AFLURIA QUADRIVALENT (dose: 0.5ml (1 as reported), batch number: 00444611A, route of administration: intramuscular, anatomical location: right arm). On 19-Oct-2017, after administration of AFLURIA QUADRIVALENT, the patient had no immediate reaction, but two days after injection client noted red, swollen area at injection site. Client stated that it never happened before and sent pic of it to telehealth provider for her employer if it does not resolve on that day. At the time of this report, the patient had not yet recovered from the events (injection site erythema, injection site swelling). The reporter assessed the case as non-serious.
Sex: F
Vaccine: FLU4
Symptoms: Paraesthesia
Clinical narrative: This spontaneous case, reported by health care professional (other) to VAERS and initially retrieved on 21-Feb-2018 by Seqirus from VAERS (VAERS ID: 721920), concerns a 38-year-old, adult, female patient. The patient's medical history and the concomitant medications were not reported. On 19-Oct-2017, the patient was administered with AFLURIA QUADRIVALENT (dose: 0.5 ml (1 as reported), route of administration: intramuscular, anatomical location: left arm, batch number and expiry date: not reported). On the same day, after vaccination, the patient had tingling in the neck and shoulder. The patient's arm, legs and behind the earlobe was still tingling. The patient did not have dizziness, swelling, redness or pain. The patient was asked to sit down and given water. It was reported that, after some time, the patient's symptoms were resolved. At the time of the report, the patient had recovered from the event (tingling). The reporter assessed the case as non-serious.
Age: 32.0
Sex: F
Vaccine: FLU4
Symptoms: Urticaria
Clinical narrative: This is spontaneous case, reported by other health professional to VAERS and initially retrieved on 21-Feb-2018 by Seqirus from VAERS (VAERS ID: 722069), concerns a 32-year-old adult female patient. The patient's historical drug included TYLENOL. On 01-Oct-2017, the patient was administered with AFLURIA QUADRIVALENT (dose: 0.5 ml, batch number XF3508, route of administration: intramuscular, anatomical location: right arm). On 23-Oct-2017, after administration of AFLURIA QUADRIVALENT, the patient had urticaria, generalized, without angioedema, which lasted for one hour, however the patient responded to diphenhydramine. At the time of this report, the outcome of the event was unknown. The reporter assessed the case as non-serious.
Age: 56.0
Sex: F
Vaccine: FLU4
Symptoms: Injection site erythema, Injection site pruritus, Injection site swelling
Clinical narrative: This spontaneous case, reported by other health professional to VAERS and initially retrieved on 21-Feb-2018 by Seqirus from VAERS (VAERS ID: 722357), concerning a 56-year-old, adult female patient. It was unknown whether the patient was using medications at the time of vaccination. The patient was allergic to penicillin and bee stings. Historical drug included: varicella vaccine. On 10-Oct-2017, the patient was administered with AFLURIA QUADRIVALENT (dose: 0.5 ml, route of administration: intramuscular, anatomical location: left arm (left deltoid), batch number: XF32708, expiry date: not reported). On the same day, the patient developed itching, redness and swelling at site of injection. The patient visited emergency department for the events. The patient was treated with prednisone (dose: 60 mg) and diphenhydramine hydrochloride (dose: 50 mg) for the events. The patient had recovered from all the events. The reporter assessed the events as non-serious.
Sex: F
Vaccine: FLU4
Symptoms: Blood glucose, Dizziness, Immediate post-injection reaction
Clinical narrative: This spontaneous case, reported by other healthcare professional (nurse) to VAERS and initially retrieved on 21-Feb-2018 by Seqirus from VAERS (VAERS ID: 722405), concerns a 38-year-old, adult, female patient. The patient's current condition's included endometriosis, asthma, left simple renal cyst, allergic rhinitis, type 2 diabetes mellitus and allergic BACTRIM, clindamycin, leeks and onions. The patient's concomitant medication included Albuterol. It was reported that patient was using ACCU-CHECK AVIVA plus test strip for blood sugar levels were tested. On 26-Sep-2017, the patient administered with AFLURIA (dose:0.5ml, route of administration: intramuscular, anatomical location: left arm, batch number: 0114621A, expiry date: not reported). On the same day, immediately after vaccination patient felt faint and dizzy. At the time of the report, the outcome of the event was recovered. The reporter considered this case as non-serious. Case correction received with IRD 21-Feb-2018: The event dizziness was made symptoms of the event immediate post-injection reaction.
Age: 12.0
Sex: M
Vaccine: FLU3
Symptoms: Cold sweat, Feeling cold, Hyperhidrosis, Injection site haemorrhage, Loss of consciousness
Clinical narrative: This spontaneous case, reported by non-health care professional (other) to VAERS and initially retrieved on 21-Feb-2018 by Seqirus from VAERS (VAERS ID: 722719), concerns a 12-year-old, adolescent, male patient. The patient's medical history and concomitant medications were not reported. On 25-Oct-2017, the patient was administered with AFLURIA (TIV) (dose: 0.5 ml (1 as reported), route of administration: intramuscular, anatomical location: left arm, batch number: XT33908 and expiry date: not reported). On the same day, after vaccination while withdrawing the needle, the patient had bleeding at the injection site and his bandage was full of blood and another bandage was applied on the top of it. The patient left the place. As the bandage was leaked the patient returned after 5 minutes and the injection spot was cleaned up. Later, the patient was fainted and blacked-out for 30 seconds and came out. Later, the patient felt clammy, cold and sweating. After some time, the patient vitals were checked by emergency medical services (EMS) and reported as normal. At the time of the report, the outcome of the events (fainting, injection site bleeding, blacked out, cold sweat and sweating) was unknown. The reporter assessed the case as non-serious.
Age: 12.0
Sex: M
Vaccine: FLU3
Symptoms: Syncope
Clinical narrative: This spontaneous case, reported by non-health care professional (other) to VAERS and initially retrieved on 21-Feb-2018 by Seqirus from VAERS (VAERS ID: 722719), concerns a 12-year-old, adolescent, male patient. The patient's medical history and concomitant medications were not reported. On 25-Oct-2017, the patient was administered with AFLURIA (TIV) (dose: 0.5 ml (1 as reported), route of administration: intramuscular, anatomical location: left arm, batch number: XT33908 and expiry date: not reported). On the same day, after vaccination while withdrawing the needle, the patient had bleeding at the injection site and his bandage was full of blood and another bandage was applied on the top of it. The patient left the place. As the bandage was leaked the patient returned after 5 minutes and the injection spot was cleaned up. Later, the patient was fainted and blacked-out for 30 seconds and came out. Later, the patient felt clammy, cold and sweating. After some time, the patient vitals were checked by emergency medical services (EMS) and reported as normal. At the time of the report, the outcome of the events (fainting, injection site bleeding, blacked out, cold sweat and sweating) was unknown. The reporter assessed the case as non-serious.
Age: 47.0
Sex: M
Vaccine: FLU4
Symptoms: Chills, Malaise, Myalgia, Pyrexia
Clinical narrative: This is a spontaneous case, reported by other healthcare professional to VAERS and initially retrieved on 21-Feb-2018 by Seqirus from VAERS (VAERS ID: 722728), concerns a 47-year-old, adult, male patient. The patient's medical history and concomitant medications were not reported. On 06-Oct-2017, the patient was administered with AFLURIA QUADRIVALENT (dose: 0.5 ml, route of administration: intramuscular, anatomical location: left arm, batch number: XF31307 and expiry date: not reported). On the same day, (reported as at 6:00 pm), after the vaccination, the patient had fever, chills, muscle aches and malaise. On 07-Oct-2017, at 08:00 am (reported as next day), the patient had recovered from the events. The reporter assessed the events as non-serious.
Age: 45.0
Sex: F
Vaccine: FLUX
Symptoms: Headache, Musculoskeletal pain, Pain, Tenderness
Clinical narrative: This is a spontaneous case, reported by other non-health professional to VAERS and initially retrieved on 03-Feb-2018 by Seqirus from VAERS (VAERS ID: 722778), concerning a 45-year-old, adult female patient. The patient's medical history and concomitant medication were not reported. On 15-Aug-2017, the patient received Influenza Vaccine (route of administration: unknown, anatomical location: left arm, dose, batch number, expiry date, trade name and manufacturer: not reported). On 17-Aug-2017, after 2 days of vaccination, the patient experienced soreness that she could not touch it. In addition, she had headache and pain across shoulders for about 1.5 months (shoulder pain). The patient had recovered from the events headache, soreness and shoulder pain. The reporter assessed this case as non-serious.
Sex: F
Vaccine: FLU4
Symptoms: Immediate post-injection reaction, Injection site bruising
Clinical narrative: This is spontaneous case, reported by other healthcare professional to VAERS and initially retrieved on 21-Feb-2018 by Seqirus from VAERS (VAERS ID: 723134), concerns a 66-year-old female patient. The patient's medical history was not reported and had no allergies. On 01-Oct-2017, the patent was administered with AFLURIA QUADRIVALENT (dose: 0.5ml, batch number: 01444621A, route of administration: intramuscular, anatomical location: right arm). On the same day after administration of vaccine, the patient had bruise at the site of injection which started immediately at the time of injection. It was reported that bruise was 3 inch by 2 inch with no abnormal pain but consistent with typical bruising. The outcome of the events was unknown. The reporter assessed the events as non-serious.
Age: 35.0
Sex: M
Vaccine: FLU4
Symptoms: Bronchitis viral, Cough, Oropharyngeal pain
Clinical narrative: This is a spontaneous case, reported by other non-health professional to VAERS and initially retrieved on 21-Feb-2018 by Seqirus from VAERS (VAERS ID: 723369), concerns a 35-year-old, adult, male patient. The patient's historical vaccine included H1N1 vaccine which caused Grave's disease, mercury poisoning and TH2 immune response (as reported). On 28-Nov-2016, the patient was administered with AFLURIA Thiomersal (dose: 0.5 ml, route of administration: intramuscular, anatomical location: left arm, batch number: 13549211A and expiry date: not reported). On an unspecified date (reported as within 5 days), the patient developed a sore throat and hard cough. The patient went to the care clinic and was diagnosed with viral bronchitis on 01-Nov-2016 (after 1 month 5 days of vaccination). The patient was treated with unspecified steroid inhaler for 6 weeks. On an unspecified date, the patient recovered from the events. The reporter assessed the events as non-serious.
Age: 35.0
Sex: F
Vaccine: FLUX, PPV
Symptoms: Injection site erythema, Injection site swelling, Pain, Pyrexia, Vomiting
Clinical narrative: This is a spontaneous case, reported by other health professional to VAERS and initially retrieved on 03-Feb-2018 by Seqirus from VAERS (regulatory reference number: 723372), concerning a 35-year-old, adult, female patient. The patient's medical history included hypothyroidism, hypertension, had nausea due to codeine, tramadol and VICODIN. The patient also had itching from VICODIN. The patient concomitant medication included levothyroxine, lisinopril/HCTZ, naltrexone, clonidine and amlodipine. On 25-Oct-2017, the patient was administered with Influenza vaccine (dose: unknown, route of administration: intramuscular, anatomical location: left arm, batch number: and expiry date: not reported). On the same day, the patient also administered with PNEUMOVAX (dose: unknown, route of administration: intramuscular, anatomical location: right arm, batch number: and expiry date: not reported). On 26-Oct-2017, 24 hrs after vaccination with PNEUMOVAX, the patient started developing redness and swelling around the injection site. On the same day, after administration of flu vaccine and PNEUMOVAX the patient also experienced fevers, body aches and vomiting. On an unknown date, the patient visited the emergency room for the events. It was reported that the patient had no topical reaction from the flu vaccine. At the time of this report, the patient had not recovered from the events. The reporter assessed the events as non-serious.
Age: 46.0
Sex: F
Vaccine: FLU4
Symptoms: Pruritus, Urticaria
Clinical narrative: This is a spontaneous case, reported by other non-healthcare professional to VAERS and initially retrieved on 21-Feb-2018 by Seqirus from VAERS (VAERS ID: 723379), concerns a 46-year-old, adult, female patient. The patient had seasonal allergies. The patient had been allergic to sulpha drugs, amoxicillin and latex. The patient had no current illness. The patient did not receive any concomitant medication. On 26-Oct-2017, the patient was administered with AFLURIA QUADRIVALENT (dose: 0.5 ml, route of administration, anatomical location, batch number and expiry date: not reported). On the same day, after the vaccination, the patient developed hives on her chest, neck, legs, arms, hands, back, feet and head. Hives were of different sizes scattered over the body and itchy. No lab investigation was done. The patient received steroid injections and antiallergic medication (unspecified), which did not subside the events. At the time of this report, the patient had not yet recovered from the events. The reporter assessed the events as non-serious.
Sex: F
Vaccine: FLU4
Symptoms: Rash
Clinical narrative: This is a spontaneous case, reported by other healthcare professional to VAERS and initially retrieved on 21-Feb-2018 by Seqirus from VAERS (VAERS ID: 723765), concerns a 55-year-old, adult, female patient. The patient's historical vaccine included seasonal influenza vaccine, which caused rash in past. The patient's medical history, allergy and concomitant medications were not reported. On 26-Oct-2017, the patient was administered with AFLURIA QUADRIVALENT (dose: 0.5 ml, route of administration: intramuscular, anatomical location: left arm, batch number: XF34809 and expiry date: not reported). On the same day, after the vaccination, the patient developed rash and she received BENADRYL (orally). On an unspecified the patient had recovered from the event. The reporter assessed the events as non-serious.
Sex: F
Vaccine: FLU4, TDAP
Symptoms: Rash, Rash erythematous, Rash pruritic, Urticaria
Clinical narrative: This spontaneous case, reported by a healthcare professional (other) to VAERS and initially retrieved on 03-Feb-2018 by Seqirus from VAERS (VAERS ID: 724039), concerns a 29-year-old, adult, female patient. The patient's current conditions included diabetes and hypothyroidism (since unspecified dates). The patient had no known allergies. The patient's concomitant medications included furosemide for unknown indication, HUMALOG for diabetes, labetalol for unknown indication and SYNTHROID for hypothyroidism (since unspecified dates). On 19-Oct-2017, the patient was administered with AFLURIA QUADRIVALENT (dose: 1 (as reported), anatomical location: right arm, route of administration: intramuscular, batch number: XF30506, expiry date: not reported) and the patient was administered with non-company suspect product, TDAP (dose: 2 (as reported), route of administration: intramuscular, anatomical location: left arm, batch number: U5810AA, expiry date not reported). On 21-Oct-2017, 3 days after vaccination, the patient had a red rash, raised above the skin, over abdomen, upper and lower extremities which caused itching. It was reported that, the patient had to visit emergency room and was diagnosed with urticaria. At the time of this report, the patient had not recovered from all the events. The reporter assessed this case as non-serious.
Age: 61.0
Sex: F
Vaccine: FLU3
Symptoms: Bedridden, Memory impairment
Clinical narrative: This spontaneous case, reported by other healthcare professional (nurse) to VAERS and initially retrieved on 21-Feb-2018 by Seqirus from VAERS (VAERS ID: 724345), concerns a 61-year-old, adult, female patient. The patient's historical condition included lung disease (she was on oxygen). The patient did not have any current illness. On 12-Oct-2017, the patient was administered with AFLURIA TIV (dose: 0.5ml (1 as reported), route of administration: unknown, anatomical location: left arm, batch number: XT32208, expiry date: not reported). On 13-Oct-2017, after 1 day of vaccination, the patient was bedridden for 36 hrs, due to this the patient was not able to remember during that period. At the time of the report, the outcome of the event was recovered. The reporter considered the case as non-serious.
Age: 59.0
Sex: F
Vaccine: FLUX
Symptoms: Injection site pain, Joint range of motion decreased, Product administered at inappropriate site, X-ray
Clinical narrative: This is a spontaneous case, reported by healthcare professional (other) to VAERS and initially retrieved on 03-Feb-2018 by Seqirus from VAERS (VAERS ID: 724391), concerns a 59-year-old, adult female patient. The patient's historical condition included right and left shoulder injury and fibromyalgia (both on an unspecified date in 2011 and resolved on an unspecified date in 2015). The patient had no current illness. On 16-Oct-2017, the patient was administered with influenza vaccine (dose: 1 (as reported), route of administration: intramuscular, anatomical location: left arm, manufacturer, trade name, batch number and expiry date: not reported). It was reported patient was vaccinated too high in her left arm shoulder. On the same day, after vaccination, approximately after 2 hours, the patient had pain, which continued and had limited range of motion. It was reported that on 03-Nov-2017, the patient started physical therapy and oral steroids were prescribed. The reporter considered this case as non-serious. Significant case correction received 03-Feb-2018: Causality for the events pain and joint range of motion decreased was changed from unassessable to related. Changes in narrative were made. Non-significant case correction received 03-Feb-2018: The causality of the event (drug administered at inappropriate  site) was added in the case comment.
Age: 35.0
Sex: F
Vaccine: FLU4
Symptoms: Paraesthesia
Clinical narrative: This spontaneous case, reported by health care professional (other) to VAERS and initially retrieved on 21-Feb-2018 by Seqirus from VAERS (VAERS ID: 724512), concerns a 35-year-old, adult, female patient. The patient's medical history and the concomitant medications were not reported. On 27-Oct-2017 at 07:25 AM, the patient was administered with AFLURIA QUADRIVALENT (dose: 0.5 ml (1 as reported), route of administration: intramuscular, anatomical location: right arm, batch number: 03144611A and expiry date: not reported). On the same day, after vaccination, at around 10 AM, the patient felt tingly on her face and left cheek. The patient was monitored for 20-30 minutes for any adverse reaction. It was reported that, the patient might have pulled her muscle in to neck earlier. At the time of the report, the patient had recovered from the event (tingling). The reporter assessed the case as non-serious.
Age: 41.0
Sex: F
Vaccine: FLU4
Symptoms: Injection site erythema, Injection site pain, Injection site swelling
Clinical narrative: This spontaneous case, reported by health care professional (other) to VAERS and initially retrieved on 21-Feb-2018 by Seqirus from VAERS (VAERS ID: 724977), concerns a 41-year-old adult female patient. On 17-Oct-2017, the patient was administered with AFLURIA QUADRIVALENT (dose: 0.5ml, route of administration: injection, anatomical location, batch number, expiry date: not reported). 19-Oct-2017, after 3 days of vaccination, the patient experienced erythematous swelling (approximately 2 cm) with raised edges and tender to palpation at the injection site. The outcome of the events had recovered. The reporter assessed this case as non-serious.
Age: 64.0
Sex: M
Vaccine: FLU3, PPV, VARZOS
Symptoms: Erythema, Hypoaesthesia, Paraesthesia, Swelling
Clinical narrative: This spontaneous case, reported by other health professional to VAERS and initially retrieved on 21-Feb-2018 by Seqirus from VAERS (VAERS ID: 725568), concerning a 64-year-old, adult male patient. The patient's concomitant medications included: LANTUS, HUMALOG, Atorvastatin and Omeprazole. On 06-Nov-2017, the patient was administered with AFLURIA (dose: 0.5 ml (reported as 1 dose), batch number: XT32308, anatomical location: left arm, route of administration, expiry date: not reported). On the same day, the patient was administered with non-company suspect drug PNEUMOVAX (1 dose, anatomical location: right arm, batch number: N019983, route of administration, expiry date: not reported) and ZOSTAVAX (1 dose, anatomical location: left arm, batch number: N0211172, route of administration, expiry date: not reported). On an unspecified date, the patient was developed redness, numbness, tingling and swelling. At the time of this report, the outcome of the events was unknown. The reporter assessed the events as non-serious. Non-significant case correction received 21-Feb-2018: Co-suspects (PNEUMOVAX and ZOSTAVAX) were added in the case comment.
Age: 73.0
Sex: F
Vaccine: FLUA3, PNC13
Symptoms: Guillain-Barre syndrome, Headache, Intensive care, Nerve conduction studies, Paraesthesia
Clinical narrative: This spontaneous case, reported by other health professional to VAERS and initially retrieved on 30-Mar-2018 by Seqirus from VAERS (VAERS ID: 726527), concerns a 73-year-old elderly female patient. The patient's current conditions included GERD (gastroesophageal reflux disease) and osteoporosis. The patient was allergic to ciprofloxacin, sulfa drugs and kiwi. The patient's concomitant medications included omeprazole, famotidine, azithromycin, multivitamin, and denosumab all for an unknown indication. On 26-Oct-2017, the patient was administered with FLUAD (TIV) (dose: 0.5 ml (reported as 1), batch number: 179501, route of administration: intramuscular, anatomical location: arm) and PREVNAR 13 (dose: 1 as reported, batch number: S51635 as reported, route of administration: intramuscular, anatomical location: arm). On 03-Nov-2017, 8 days after vaccination, the patient presented in the ED (emergency department) with new onset of headache and paraesthesia consistent with Guillain-Barre syndrome. The patient was then transferred to the neurocritical intensive care unit with deteriorating respiratory status. On 07-Nov-2017, motor and sensory examination and on 08-Nov-2017, motor conduction study was performed for which result not provided. The patient was admitted in the hospital for 9 days. Currently, the patient was still on an unspecified treatment. At the time of report, the patient had not yet recovered from the event Guillain-Barre syndrome. The reporter considered the event as serious due to hospitalization.
Age: 73.0
Sex: F
Vaccine: FLUA3, PNC13
Symptoms: Respiratory disorder
Clinical narrative: This spontaneous case, reported by other health professional to VAERS and initially retrieved on 30-Mar-2018 by Seqirus from VAERS (VAERS ID: 726527), concerns a 73-year-old elderly female patient. The patient's current conditions included GERD (gastroesophageal reflux disease) and osteoporosis. The patient was allergic to ciprofloxacin, sulfa drugs and kiwi. The patient's concomitant medications included omeprazole, famotidine, azithromycin, multivitamin, and denosumab all for an unknown indication. On 26-Oct-2017, the patient was administered with FLUAD (TIV) (dose: 0.5 ml (reported as 1), batch number: 179501, route of administration: intramuscular, anatomical location: arm) and PREVNAR 13 (dose: 1 as reported, batch number: S51635 as reported, route of administration: intramuscular, anatomical location: arm). On 03-Nov-2017, 8 days after vaccination, the patient presented in the ED (emergency department) with new onset of headache and paraesthesia consistent with Guillain-Barre syndrome. The patient was then transferred to the neurocritical intensive care unit with deteriorating respiratory status. On 07-Nov-2017, motor and sensory examination and on 08-Nov-2017, motor conduction study was performed for which result not provided. The patient was admitted in the hospital for 9 days. Currently, the patient was still on an unspecified treatment. At the time of report, the patient had not yet recovered from the event Guillain-Barre syndrome. The reporter considered the event as serious due to hospitalization.
Age: 41.0
Sex: F
Vaccine: FLU4
Symptoms: Pruritus generalised
Clinical narrative: This spontaneous case, reported by other healthcare professional to VAERS and initially retrieved on 21-Feb-2018 by Seqirus from VAERS (VAERS ID: 726594), concerns a 41-year-old, adult female patient. The patient was allergic to drugs [PERCOCET, amoxicillin, iodine contrast, VICODIN, VIRACEPT, Levofloxacin and ACIPHEX]. On 21-Sep-2017, the patient was administered with AFLURIA QUADRIVALENT (dose: 0.5 ml, route of administration: intramuscular, anatomical location: left arm, batch number and expiry date: not reported). On the same day (21-Sep-2017) of vaccination, the patient experienced generalized pruritus. It was reported that, the patient received BENADRYL (25 mg via oral route) for the event. On an unspecified date, the patient had recovered from the event (generalized pruritus). The reporter considered this case as non-serious.
Age: 49.0
Sex: F
Vaccine: FLU4
Symptoms: Pruritus, Rash erythematous
Clinical narrative: This spontaneous case, reported by other non-health professional to VAERS and initially retrieved on 21-Feb-2018 by Seqirus from VAERS (VAERS ID: 727419), concerning a 49-year-old, adult female patient. The patient's current condition included: seafood allergy. Concomitant medication included: probiotics. On 07-Nov-2017, the patient was administered with AFLURIA QUADRIVALENT (dose: 0.5 ml (reported as 1 dose), route of administration: intramuscular, anatomical location: left arm, batch number, expiry date: not reported). On the same day, few hours after injection, the patient's felt itchy at the skin area. In addition, she had small red bump. The patient reported that, the injection site was close to her BCG (Bacillus Calmette-Guerin) scar. The itchiness lasted until next day and gradually subsided. The last time the patient checked, the skin was red with a couple of bumps. At the time of this, the outcome of the events was not reported. The reporter assessed the events as non-serious.
Sex: M
Vaccine: FLUA3
Symptoms: Asthenia, Cerebellar syndrome, Guillain-Barre syndrome
Clinical narrative: This serious spontaneous case, reported by other health professional to VAERS and initially retrieved on 30-Mar-2018 by Seqirus from VAERS (VAERS ID: 727963), concerning a 70-year-old, elderly, male patient. The patient's historical condition included: pulmonary emboli. Current condition included: metastatic esophageal carcinoma. Concomitant medications included: 5-Fluorouracil, TYLENOL, Ascorbic acid, Atenolol, Vitamin B12, Ferrous sulfate, BREO ELLIPTA, FLORAJEN3, Mag oxide, Melatonin, PROTONIX, COMPAZINE and FLOMAX. On 27-Sep-2017, the patient was administered with FLUAD (TIV) (dose: 0.5 ml (reported as 1 dose), route of administration: intramuscular, anatomical location: right arm, batch number: 178701 (reported as 1787701), expiry date: not reported). Approximately 2 days after vaccination, the patient was suspected of cerebellar syndrome which was possibly related to 5-FU (Fluorouracil) infusion (as reported). On 29-Sep-2017, 2 days after vaccination, the patient developed progressive weakness and subsequently he was diagnosed with Guillain-Barre syndrome (GBS). The reporter considered the event (GBS) was related to the flu vaccine. It was reported that, the patient was doing better he could lift his legs and stand. At the time of this report, the patient was still recovering from the event Guillain-Barre Syndrome.
Sex: M
Vaccine: FLU4, PPV
Symptoms: Injection site erythema, Injection site pain, Local reaction, Rash
Clinical narrative: This is a spontaneous case, reported by other healthcare professional to VAERS and initially retrieved on 21-Feb-2018 by Seqirus from VAERS (VAERS ID: 728814), concerns a 69-year-old. elderly, male patient. The patient had no medical history. The patient's concomitant medications included alfuzosin hydrochloride, Artificial tears PVA, Povidone PF UD, atorvastatin calcium, desonide, metformin hydrochloride, Fish oil concentrate, Garlic oil, mometasone furoate and sodium chloride. On 02-OCt-2017, the patient was administered with AFLURIA QUADRIVALENT (dose: 0.5 ml, route of administration: injection (reported as SYR), anatomical location: right arm, batch number: XF31607 and expiry date: not reported. On 04-Oct-2017, after 2 days of PNEUMOVAX vaccination, the patient went to the scheduled dermatology appointment, where it was observed that, he had a local injection reaction, which included erythema and tenderness at injection site. On the same day, patient also had rash. On an unspecified date, the patient had recovered from the events. The reporter assessed the event as non-serious.
Age: 31.0
Sex: F
Vaccine: FLU3
Symptoms: Nuclear magnetic resonance imaging, Pain in extremity, Product administered at inappropriate site, X-ray
Clinical narrative: This spontaneous case, reported by healthcare professional to VAERS and initially retrieved on 21-Feb-2018 by Seqirus from VAERS (VAERS ID: 728836), concerns a 31-year-old, adult female patient. The patient did not have any medical history and current illness. On 26-Oct-2017, the patient was administered with AFLURIA (dose: 0.5 ml (reported as 1), route of administration: intramuscular, anatomical location: left arm, batch number: XT30106 and expiry date: not reported). On the same day after vaccination, the patient experienced severe and prolonged pain in arm (pain in arm). Reportedly, the vaccine was not given in appropriate location on arm. On an unspecified date, the patient had physician office visit and underwent MRI (magnetic resonance imaging) and X-ray (results not reported). Outcome of the event pain in arm was reported as unknown. The reporter assessed this report as non-serious.
Age: 53.0
Sex: F
Vaccine: FLU3
Symptoms: Cough, Oropharyngeal pain, Poor quality sleep, Swelling face
Clinical narrative: This spontaneous case, reported by other healthcare professional to VAERS and initially retrieved on 21-Feb-2018 by Seqirus from VAERS (VAERS ID: 729278), concerns a 53-year-old, adult female patient. The patient had no medical history, allergies or current conditions. On 01-Dec-2017, the patient was administered with AFLURIA (TIV) (dose: 0.5 ml (reported as 1), route of administration: unknown (as reported), anatomical location: right arm, batch number: XT59305, expiry date: not reported). On the same day of vaccination, the patient developed sore throat and after 4 hours had cough. The patient slept poorly that night. On 02-Dec-2017, (next morning), the patient woke up with swollen face. The patient took BENADRYL and felt better. At the time of this report, the patient was recovering from the events (sore throat, cough, swollen face and poor sleep). The reporter assessed the case as non-serious.
Age: 84.0
Sex: M
Vaccine: FLU4
Symptoms: Rash
Clinical narrative: This is a spontaneous case, reported by other healthcare professional to VAERS and initially retrieved on 21-Feb-2018 by Seqirus from VAERS (VAERS ID: 729724), concerning an 84-year-old, elderly, male patient. The patient had no historical condition or allergies. The patient's current status was healthy. The patient's concomitant medication was not reported. On 04-Oct-2017, the patient was administered with AFLURIA QUADRIVALENT (dose: 0.5 ml, route of administration: injection (reported as SYR), anatomical location: right arm, batch number: XF33108 and expiry date: not reported). On 06-Oct-2017, after 2 days of vaccination, the patient developed skin rash and went to the emergency room. On an unspecified date, the patient had recovered from the event. The reporter assessed the event as non-serious.
Age: 47.0
Sex: M
Vaccine: FLU4
Symptoms: Arthralgia, Chills, Fatigue, Headache, Myalgia
Clinical narrative: This spontaneous case, reported by non-health care professional (other) to VAERS and initially retrieved on 11-Mar-2018 by Seqirus from VAERS (VAERS ID: 730682), concerns a 47-year-old adult male patient. On 14-Dec-2017, the patient was administered with AFLURIA QUADRIVALENT (dose: 0.5ml, route of administration: intramuscular, anatomical location: left arm, batch number and expiry date: not reported). On the same day (14-Dec-2017), after vaccination, the patient experienced chills, fever, vomiting, headache, shaking, sore muscle and joints all over and felt very tired. At the time of this report, the patient had not recovered from all the events. The reporter assessed this case as non-serious.
Age: 47.0
Sex: M
Vaccine: FLU4
Symptoms: Pyrexia, Tremor, Vomiting
Clinical narrative: This spontaneous case, reported by non-health care professional (other) to VAERS and initially retrieved on 11-Mar-2018 by Seqirus from VAERS (VAERS ID: 730682), concerns a 47-year-old adult male patient. On 14-Dec-2017, the patient was administered with AFLURIA QUADRIVALENT (dose: 0.5ml, route of administration: intramuscular, anatomical location: left arm, batch number and expiry date: not reported). On the same day (14-Dec-2017), after vaccination, the patient experienced chills, fever, vomiting, headache, shaking, sore muscle and joints all over and felt very tired. At the time of this report, the patient had not recovered from all the events. The reporter assessed this case as non-serious.
Age: 46.0
Sex: M
Vaccine: FLU4
Symptoms: Electromyogram, Neck pain, Nuclear magnetic resonance imaging, Pain in extremity
Clinical narrative: This spontaneous case, reported by other health professional to VAERS and initially retrieved on 11-Mar-2018 by Seqirus from VAERS (VAERS ID: 730689), concerning a 46-year-old, adult male patient. The patient was allergic to morphine. Concomitant medications included: lisinopril, vitamin D3, vitamin B12, fish oil, Magnesium, vitamin C and multivitamin for an unknown indication. On 01-Oct-2017, the patient was administered with AFLURIA QUADRIVALENT (dose: 0.5 ml, route of administration: intramuscular, anatomical location: left arm, batch number: 00844611A, expiry date: not reported). On 14-Oct-2017, after 13 days of vaccination, the patient experienced pain in left arm and neck pain. On 27-Oct-2017, the patient made his visit to the emergency room/physician's office visit. On the same day and on 30-Oct-2017, magnetic resonance imaging (MRI) was performed but the results were not reported. On 01-Nov-2017 and 13-Dec-2017, electromyogram (EMG) was performed but the results were not reported. At the time of report, the patient had not yet recovered from the events (neck pain and painful left arm). The reporter assessed the events as non-serious.
Age: 63.0
Sex: F
Vaccine: FLU4
Symptoms: Injected limb mobility decreased, Injection site pain
Clinical narrative: This spontaneous case, reported by health care professional (other) to VAERS and initially retrieved on 11-Mar-2018 by Seqirus from VAERS (VAERS ID: 730764), concerns a 63-year-old adult female patient. On 14-Nov-2017, the patient was administered with AFLURIA QUADRIVLAENT (dose: 0.5ml, route of administration: intramuscular, anatomical location: left arm, batch number: 100944611A and expiry date: not reported). On the same day of vaccination, the patient experienced muscle soreness in shoulder/upper arm where the vaccine was administered. The patient can only lift her arm half a way up. It was reported that, the patient felt pain more during morning after the sleep all the night and pain goes away for a little while during the daytime. At the time of this report, the outcome of the events was not recovered. The reporter assessed this case as non-serious.
Age: 60.0
Sex: F
Vaccine: FLU4, PPV
Symptoms: Body temperature increased, Contusion, Discomfort, Injection site erythema, Injection site pruritus
Clinical narrative: This spontaneous case, reported by other healthcare professional to VAERS and initially retrieved on 11-Mar-2018 by Seqirus from VAERS (VAERS ID: 730932), concerns a 60-year-old, adult female patient. On 17-Nov-2017, the patient was administered with AFLURIA QUADRIVALENT (dose: 0.5 ml (reported as unknown), route of administration: unknown, anatomical location: left arm, batch number: XF33008, expiry date: not reported) and PNEUMOVAX (dose: unknown, route of administration: unknown, anatomical location: left arm, batch number: N003997, expiry date: not reported). On 18-Nov-2017, the next day of vaccination (reported as 24 to 30 hrs), the patient experienced soreness and discomfort. The patient also had elevated body temperature along with redness and itching at the injection site. The patient took BENADRYL (from 19-Nov-2017 to 20-Nov-2017), but was not effective. On 21-Nov-2017, the patient consulted physician and was prescribed with prednisone 20 mg, 1 tablet bid for 5 days. It was reported that, the patient had improved, but had some soreness and bruising. It was reported that, no lab data was performed. At the time of this report, the patient had recovered from the events. The reporter assessed the case as non-serious. Non-significant case correction received 11-Mar-2018: Case comment was corrected (added co-suspect).
Age: 60.0
Sex: F
Vaccine: FLU4, PPV
Symptoms: Pain
Clinical narrative: This spontaneous case, reported by other healthcare professional to VAERS and initially retrieved on 11-Mar-2018 by Seqirus from VAERS (VAERS ID: 730932), concerns a 60-year-old, adult female patient. On 17-Nov-2017, the patient was administered with AFLURIA QUADRIVALENT (dose: 0.5 ml (reported as unknown), route of administration: unknown, anatomical location: left arm, batch number: XF33008, expiry date: not reported) and PNEUMOVAX (dose: unknown, route of administration: unknown, anatomical location: left arm, batch number: N003997, expiry date: not reported). On 18-Nov-2017, the next day of vaccination (reported as 24 to 30 hrs), the patient experienced soreness and discomfort. The patient also had elevated body temperature along with redness and itching at the injection site. The patient took BENADRYL (from 19-Nov-2017 to 20-Nov-2017), but was not effective. On 21-Nov-2017, the patient consulted physician and was prescribed with prednisone 20 mg, 1 tablet bid for 5 days. It was reported that, the patient had improved, but had some soreness and bruising. It was reported that, no lab data was performed. At the time of this report, the patient had recovered from the events. The reporter assessed the case as non-serious. Non-significant case correction received 11-Mar-2018: Case comment was corrected (added co-suspect).
Age: 47.0
Sex: F
Vaccine: FLU4
Symptoms: Cough, Dyspnoea, Headache, Throat tightness
Clinical narrative: This spontaneous case, reported by other healthcare professional to VAERS and initially retrieved on 11-Mar-2018 by Seqirus from VAERS (VAERS ID: 731272), concerns a 47-year-old, adult female patient. The patient's current conditions included asthma (since 33-year-old), bronchitis and had drug allergy (acetylsalicylic acid and ibuprofen). The patient had no concomitant medications and lab data. On 19-Dec-2017, the patient was administered with AFLURIA QUADRIVALENT (dose: 0.5 ml (reported as 1), route of administration: intramuscular, anatomical location: left Arm, batch number: XF35109, expiry date: not reported). Around 04:00 PM, on the same day, the patient experienced headache. At around 06:45 PM (during dinner) felt like throat was being closed. The patient also had cough and respiratory difficulties. The patient took ZYRTEC 10 mg oral over the counter (OTC). On an unspecified date, the patient had recovered from the events. The reporter assessed the case as non-serious. Non-significant case correction received on 11-Mar-2018: Narrative was corrected.
Age: 2.0
Sex: F
Vaccine: FLU4, TDAP
Symptoms: Injection site erythema
Clinical narrative: This is spontaneous case, reported by Other Health Professional to VAERS and initially retrieved on 11-Mar-2018 by Seqirus from VAERS (VAERS ID: 731648), concerns a 2-year-old female infant patient. The patient's current condition included asthma and had stomach bug for 24 hrs (2 weeks ago). The patient's adverse event prior to vaccination was rash with MMR (Measles, mumps, rubella vaccine). On 21-Dec-2017, the patient was administered with AFLURIA QUADRIVALENT (dose: 05 ml (N/A as reported), route of administration: injection (SYR as reported), anatomical location: left leg, batch number: not reported). On the same day, the patient was also administered with ADACEL (dose: Unk as reported), route of administration: injection (SYR as reported), anatomical location: right leg, batch number: not reported). On 22-Dec-2017, the patient had spreading redness on thigh. At the time of this report, the patient had not yet recovered from the event. The reporter assessed the case as non-serious.